Company Presentation


Country:Switzerland and USA
Category:Clinical Stage Biotech Company
Date:April 24, 2023
Time:15:30 – 15:45
Speaker:Dr. Theresa Visarius, Managing Director Immunophotonics Switzerland (IPS Biopharma AG)

Company profile

Immunophotonics, Inc. is a privately owned clinical stage biotech that provides an innovative solution to combat solid metastatic cancers. The company is in phase 2 multi-indication clinical development of IP-001, an immune-stimulating drug designed to induce tumor-specific, potent antitumor immune activation. Early clinical data show shrinkage of both treated tumors and distant metastases. IP-001 is the first asset in clinical development from broad intellectual property.

Further information

Follow us